anonymous
Guest
anonymous
Guest
The first few years of Kesimpta was good. Now it's big Pharma tactics with no bonus. The amount of field rides are crazy. What happened to once every 6 weeks. Now it's every two weeks. Customers are sick of seeing them. Novartis is hurting their business with this outdated tactic.I launched Gilenya, it was never great. Sometimes we made great bonus but it was always “the sky is falling.” Non stop initiatives and pressure